BioSpace News Archive

Alpha Teknova, Inc. today announced the Company’s upcoming presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting, where they will share data on novel products in development that address critical pain points in AAV gene therapy bioproduction.

Pliant Therapeutics, Inc. today announced participation in the following May investor events.

Marizyme, Inc. announced that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.

SeaStar Medical Holding Corporation announces that Eric Schlorff, CEO, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 2:30 p.m. Eastern time.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2023 financial results and business updates.

Microbion Corporation announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, announced the appointment of industry veteran Mark Alles as Chair of the Board of Directors.

Scholar Rock today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 28,100 shares of common stock.

Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a targeted therapy in two indications: in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.

LadRx Corporation today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares.